PCVX
VAXCYTE Hires Ex-Pfizer Vaccine Chief, Narrows VAX-31 Data Timing
Vaxcyte named Luis Jodar CMO and David McAvoy CLO, and now expects OPUS-1 Phase 3 topline data by the end of October 2026.
PCVX
Market-moving news on Vaxcyte (NASDAQ: PCVX): filings, earnings, deals and other events, from REDFILED.